SCHEMBL514383

SCHEMBL514383

CS(=O)(=O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.65
KIF11 P52732 1/20 0.54
FFAR4 Q5NUL3 2/20 0.53
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50
HTR2A P28223 1/20 0.47
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP14 P50281 1/20 0.46
PTGS1 P23219 1/20 0.45
ENPP2 Q13822 1/20 0.45
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
EPHX2 P34913 1/20 0.44
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
TP53 P04637 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673984 0.94 PTGS2 (0.68) PTGS2KIF11FFAR4BCHEACHE
SCHEMBL6925883 0.94 PTGS2 (0.60) PTGS2KIF11FFAR4BCHEACHE
SCHEMBL13429325 0.84 EPHX2 (0.73) PTGS2EPHX2TP53
SCHEMBL8941548 0.82 PTGS2 (0.50) PTGS2FFAR4MMP2MMP9MMP14
SCHEMBL13542559 0.81 FFAR4 (0.50) PTGS2KIF11FFAR4BCHEACHE
SCHEMBL13551948 0.81 ENPP2 (0.46) PTGS2PTGS1ENPP2SMN1; SMN2
SCHEMBL3649085 0.81 CA12 (0.50) PTGS2KIF11BCHEACHEEPHX2
SCHEMBL14572900 0.80 MMP2 (0.55) PTGS2KIF11FFAR4BCHEACHE
SCHEMBL13290857 0.80 FFAR4 (0.50) PTGS2KIF11FFAR4BCHEACHE
SCHEMBL16451188 0.80 ALDH1A1 (0.52) PTGS2KIF11FFAR4BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795340-B2 Compositon sensitive to UV-C radiation and UV-C sterilization or disinfection dosimeter TERRAGENE S.A. (AR) 2023-10-24 US claimed
EP-3964554-A1 COMPOSITON SENSITIVE TO UV-C RADIATION AND UV-C STERILIZATION OR DISINFECTION DOSIMETER Terragene LLC (US) 2022-03-09 EP claimed
EP-4393923-A1 PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION Yiyou Biotech (Shanghai) Co., Ltd. (CN) 2024-07-03 EP disclosed
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
US-11795340-B2 Compositon sensitive to UV-C radiation and UV-C sterilization or disinfection dosimeter TERRAGENE S.A. (AR) 2023-10-24 US disclosed
WO-2023115327-A1 PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION 中国药科大学 2023-06-29 WO disclosed
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP disclosed
EP-3964554-A1 COMPOSITON SENSITIVE TO UV-C RADIATION AND UV-C STERILIZATION OR DISINFECTION DOSIMETER Terragene LLC (US) 2022-03-09 EP disclosed
US-11072634-B2 Inhibitors of transglutaminases ZEDIRA GMBH (DE) 2021-07-27 US disclosed
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-04-01 US disclosed
EP-3223822-B1 BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS ENANTA PHARM INC (US) 2020-07-01 EP disclosed
WO-2008055488-A1 MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS ZEDIRA GMBH (DE) 2008-05-15 WO disclosed
US-20070167476-A1 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds 3M INNOVATIVE PROPERTIES COMPANY 2007-07-19 US disclosed
US-20070167476-A1 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds 3M INNOVATIVE PROPERTIES COMPANY 2007-07-19 US disclosed
EP-1803709-A1 PROTON PUMP INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2007-07-04 EP disclosed
US-7214698-B2 Beta-agonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-05-08 US disclosed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 US disclosed
US-20070060754-A1 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2007-03-15 US disclosed
US-20070060754-A1 Alkoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2007-03-15 US disclosed
US-20070037834-A1 Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection KYOWA HAKKO KIRIN CO., LTD. (JP) 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060754-A1 Alkoxy substituted imidazoquinolines IL2, IFNG, IRF3 PTGS2 465/4885KIF11 4644/4885FFAR4 2364/4885
US-20070167476-A1 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds IL4, IL2, IL5 PTGS2 594/4885KIF11 2726/4885FFAR4 1307/4885
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 PTGS2 1751/4885KIF11 4573/4885FFAR4 2677/4885
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 PTGS2 146/4885KIF11 2454/4885FFAR4 2910/4885
US-20070037834-A1 Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection CX3CR1, CCL5, CCRL2 PTGS2 3538/4885KIF11 3982/4885FFAR4 811/4885
US-11072634-B2 Inhibitors of transglutaminases TGM2, TGM3, TGM1 PTGS2 282/4885KIF11 4527/4885FFAR4 4526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.